Biocon

335.90
+17.00
(5.33%)
ann
There are new updates from the company19 hours ago
Viewcross
right
Market Cap
40,328.15 Cr
EPS
8.55
PE Ratio
49.48
Dividend Yield
0.16 %
Industry
Healthcare
52 Week High
404.70
52 Week Low
269.55
PB Ratio
1.82
Debt to Equity
0.91
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from15 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+60.00 %
+60.00 %
Hold
Hold+20.00 %
+20.00 %
Sell
Sell+20.00 %
+20.00 %

Company News

View All News
Caret
positive
Biocon Ltd.: Subsidiary Secures Major US Market Access for Biosimilar Yesintek18 hours ago
Biocon Biologics, a subsidiary of Biocon Ltd., has secured multiple market access agreements for Yesintek, its biosimilar to Stelara, covering over 100 million lives in the US. Major health insurers including Express Scripts, Cigna, United Healthcare, CVS Health, and Optum Rx have added Yesintek to their formularies, effective from various dates in 2025. The drug is approved for treating several autoimmune diseases and is available in multiple formulations.
positive
Biocon Biologics Achieves Strong Market Access for Yesintek in US18 hours ago
Biocon Biologics has secured significant market access coverage for Yesintek in the United States, reaching over 100 million lives. This development suggests a successful launch and potential widespread adoption of the product in the US healthcare market.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,836.60
#1 4,40,661.86
37.20
#1 49,887.20
12.06
#1 9,648
13.77
62.24
6,124.50
1,62,586.23
78.35
8,184.00
0.89
1,600
#1 64.53
60.86
1,542.90
1,24,606.91
24.70
26,520.70
14.17
4,155
47.38
57.59
3,285.20
1,11,186.10
59.18
10,785.70
11.59
1,656
13.54
54.31
2,415.40
99,654.22
48.14
10,615.60
19.57
1,942
-16.38
46.37
1,171.30
97,739.76
#1 18.38
28,905.40
12.36
5,578
1.69
51.52
2,085.30
95,202.48
32.75
20,141.50
#1 19.94
1,936
38.82
54.25
892.50
89,806.38
19.65
19,831.50
13.82
3,831
29.92
53.95
1,242.00
72,135.56
19.97
29,559.20
17.55
3,169
-10.04
59.05
30,725.00
65,288.48
48.97
6,097.20
10.80
1,201
16.01
55.94
Growth Rate
Revenue Growth
35.25 %
Net Income Growth
101.84 %
Cash Flow Change
59.45 %
ROE
79.37 %
ROCE
103.31 %
EBITDA Margin (Avg.)
6.64 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
952
778
800
811
1,223
1,029
989
1,086
974
986
1,025
1,098
1,242
1,193
1,564
1,585
1,557
1,483
1,673
1,784
1,621
1,712
1,765
1,885
2,060
1,808
1,945
2,223
2,476
2,217
2,384
3,020
3,929
3,516
3,551
4,135
3,966
4,543
3,604
3,826
Expenses
653
606
727
615
740
719
706
762
738
735
786
836
937
886
982
1,160
1,137
1,029
1,174
1,307
1,247
1,284
1,363
1,459
1,476
1,427
1,515
1,733
1,911
1,783
1,894
2,624
2,820
2,741
2,769
3,051
3,013
2,813
2,905
3,070
EBITDA
300
172
73
196
483
309
283
324
236
250
239
262
306
307
582
425
420
454
499
477
373
428
402
427
584
380
430
489
565
434
490
396
1,109
775
782
1,084
953
1,730
699
756
Operating Profit %
21 %
20 %
6 %
22 %
21 %
27 %
25 %
27 %
20 %
21 %
19 %
21 %
20 %
21 %
26 %
25 %
26 %
29 %
25 %
25 %
20 %
24 %
22 %
21 %
20 %
19 %
18 %
20 %
21 %
17 %
18 %
11 %
25 %
20 %
18 %
14 %
23 %
17 %
18 %
19 %
Depreciation
59
59
61
64
65
66
68
70
73
99
94
97
95
99
112
117
120
124
132
144
152
167
178
186
184
195
202
206
212
218
231
301
364
358
389
415
407
405
420
425
Interest
0
4
3
2
21
6
7
9
5
16
14
15
17
18
19
19
16
17
14
18
17
13
7
5
34
20
23
15
11
20
30
120
249
233
248
267
227
236
226
223
Profit Before Tax
249
165
20
141
409
238
208
245
159
135
132
150
193
190
451
289
284
313
354
315
204
249
218
236
366
166
206
269
343
197
229
-26
497
184
214
808
319
1,146
98
156
Tax
32
34
18
19
55
55
42
54
10
38
43
36
41
52
73
46
41
85
100
85
45
81
22
49
69
57
46
49
59
30
147
-5
82
35
42
55
96
284
71
75
Net Profit
217
131
2
122
354
182
167
191
148
98
89
114
153
138
378
243
243
228
254
230
159
168
195
187
296
108
160
220
284
167
82
-21
415
149
173
753
223
862
27
81
EPS in ₹
10.08
6.31
-0.54
5.30
16.97
8.49
7.48
8.72
6.49
1.38
1.17
1.56
2.21
1.02
3.00
3.67
3.61
1.74
1.82
1.71
1.04
1.26
1.39
1.42
2.13
0.71
1.16
1.57
2.00
1.21
0.39
-0.35
2.62
0.85
1.05
5.52
1.13
5.51
-0.13
0.21

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
6,375
8,458
9,394
9,990
12,192
14,444
18,522
20,394
52,043
56,071
Fixed Assets
1,630
1,749
3,626
3,700
4,471
5,971
6,364
6,569
29,468
30,644
Current Assets
2,563
3,971
4,048
4,149
4,889
5,325
7,600
8,382
12,334
15,179
Capital Work in Progress
1,677
2,240
839
1,303
1,899
2,196
2,800
4,110
7,317
7,993
Investments
230
901
1,253
675
1,012
966
1,952
1,588
2,069
1,000
Other Assets
2,839
3,569
3,676
4,312
4,811
5,311
7,406
8,127
13,189
16,434
Total Liabilities
6,375
8,458
9,394
9,990
12,192
14,444
18,522
20,394
52,043
56,071
Current Liabilities
1,555
1,666
1,678
2,141
3,039
4,008
4,210
3,828
8,511
15,359
Non Current Liabilities
1,378
2,493
2,502
2,200
2,447
3,053
5,805
7,096
21,043
15,437
Total Equity
3,443
4,300
5,214
5,649
6,707
7,383
8,508
9,470
22,489
25,275
Reserve & Surplus
3,171
3,992
4,738
4,881
5,798
6,106
7,027
7,832
17,267
19,183
Share Capital
100
100
100
300
300
600
600
600
600
600

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-94
300
-47
-261
210
165
72
-243
641
-380
Investing Activities
-491
-1,138
-510
-684
-703
-1,505
-3,651
-1,662
-14,260
-1,002
Operating Activities
211
371
640
662
1,155
1,283
1,160
1,177
1,853
2,954
Financing Activities
186
1,068
-178
-240
-242
388
2,564
242
13,049
-2,333

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
60.67 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
60.64 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
7.96 %
6.55 %
5.63 %
5.90 %
5.93 %
5.66 %
5.66 %
DIIs
6.65 %
6.89 %
6.87 %
6.83 %
7.79 %
7.30 %
7.76 %
8.63 %
11.90 %
12.56 %
14.08 %
14.51 %
13.68 %
14.30 %
14.44 %
15.37 %
15.72 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
10.89 %
11.03 %
11.49 %
11.37 %
10.87 %
10.72 %
12.07 %
12.46 %
13.21 %
13.34 %
13.61 %
14.47 %
15.53 %
14.63 %
14.57 %
14.07 %
13.63 %
Others
21.79 %
21.44 %
21.00 %
21.16 %
20.70 %
21.35 %
19.54 %
18.27 %
14.26 %
13.46 %
3.70 %
3.83 %
4.52 %
4.53 %
4.42 %
4.27 %
4.34 %
No of Share Holders
0
3,11,349
3,38,815
3,63,447
3,64,502
3,47,911
3,41,016
3,69,816
4,11,086
4,12,441
4,15,046
4,34,339
4,70,261
4,43,513
4,39,503
4,27,705
4,24,297

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 3 1 1 0.00 0.00 0.5 1.5 0.5 0.00
Dividend Yield (%) 0.00 1.01 0.33 0.37 0.00 0.00 0.25 0.57 0.15 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
08 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 May 2025 339.10 318.65
30 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 Jan 2025 372.95 355.70
30 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 Oct 2024 370.65 326.85
09 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Aug 2024 311.90 339.20
05 Jul 2024 DIVIDEND Dividend
₹ 0.50 /share
05 Jul 2024 311.90 361.10
07 Jul 2023 DIVIDEND Dividend
₹ 1.50 /share
07 Jul 2023 240.45 259.50
01 Jul 2022 DIVIDEND Dividend
₹ 0.50 /share
30 Jun 2022 382.30 308.40
13 Jun 2019 BONUS Bonus
1:1
12 Jun 2019 271.45 257.90

Announcements

Shareholder Meeting / Postal Ballot-Notice of Postal Ballot12 hours ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release19 hours ago
Intimation Of Record Date For Commercial Papers5 days ago
Redemption Of Commercial Papers6 days ago
Company Statement Dated April 26 20259 days ago
Board Meeting Outcome for Outcome Of Board MeetingApr 23, 2025
Issue Of Commercial PapersApr 22, 2025
Board Meeting Intimation for To Consider And Approve The Proposal For Raising Of Funds.Apr 20, 2025
Announcement under Regulation 30 (LODR)-Credit RatingApr 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 14, 2025
Notification To Stock ExchangesApr 10, 2025
Certificate Pursuant To SEBI Master Circular No. SEBI/HO/DDHS/Pod1/P/CIR/2024/54 Dated May 22 2024.Apr 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 10, 2025
Board Meeting Outcome for Outcome Of Board Meeting - Disclosure Under Reg 30Apr 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 02, 2025
Board Meeting Intimation for Board Meeting IntimationApr 02, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportApr 02, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotApr 02, 2025
Announcement under Regulation 30 (LODR)-CessationApr 01, 2025
Board Meeting Intimation for Intimation For The Board Meeting Pursuant To Regulation 29(1)(D) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - Raising Of FundsApr 01, 2025
Announcement Under Regulation 30Mar 29, 2025
Reminder Letter To Shareholders For Claiming Unclaimed Dividend And Updation Of KYC InformationMar 28, 2025
Closure of Trading WindowMar 28, 2025
Notification To Stock ExchangeMar 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 06, 2025
Notification To Stock ExchangesMar 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 28, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 27, 2025
Announcement Under Regulation 30Feb 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 24, 2025
Notification To Stock ExchangeFeb 18, 2025
Record Date Intimation For Commercial PapersFeb 17, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 07, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 06, 2025
Corporate PresentationFeb 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 01, 2025
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015Feb 01, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionJan 31, 2025
Integrated Filing (Financial)Jan 31, 2025
Recording Of Q3 FY 25 Earnings CallJan 31, 2025
Presentation Of Q3 FY 25 Earnings CallJan 31, 2025

Technical Indicators

RSI(14)
Neutral
54.08
ATR(14)
Volatile
11.48
STOCH(9,6)
Neutral
41.57
STOCH RSI(14)
Neutral
71.55
MACD(12,26)
Bullish
0.63
ADX(14)
Weak Trend
12.32
UO(9)
Bearish
49.49
ROC(12)
Uptrend And Accelerating
2.14
WillR(14)
Overbought
-11.59

About Biocon

Biocon Limited is India's largest fully-integrated biopharmaceutical company, focusing on biotechnology products and research services. Founded in 1978, Biocon specializes in treating diabetes, cancer, and autoimmune diseases. The company develops and commercializes novel biologics, biosimilars, complex small molecule APIs, and generic formulations for global markets. Biocon's product portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, and oncology treatments. The company operates manufacturing facilities in Bangalore, Hyderabad, and Visakhapatnam, utilizing various technology platforms such as microbial fermentation, chromatographic purification, chemical synthesis, and peptide synthesis. Biocon has expanded its global presence through strategic partnerships and has launched several biosimilar and generic products in international markets, including the United States, Europe, and emerging economies.
Listing Date
07 Apr, 2004(21 Years, -1 days)
Chairperson NameKiran Mazumdar Shaw